Lee Danner & Bass Inc. lowered its stake in shares of iShares Russell 1000 ETF (NYSEARCA:IWB) by 8.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,370 shares of the company’s stock after selling 570 shares during the quarter. Lee Danner & Bass Inc.’s holdings in iShares Russell 1000 ETF were worth $997,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. HC Financial Advisors Inc. acquired a new position in iShares Russell 1000 ETF during the 4th quarter worth $494,000. RMB Capital Management LLC boosted its position in iShares Russell 1000 ETF by 21.9% during the 1st quarter. RMB Capital Management LLC now owns 10,980 shares of the company’s stock worth $1,613,000 after acquiring an additional 1,975 shares during the period. Jump Trading LLC acquired a new position in iShares Russell 1000 ETF during the 1st quarter worth $1,100,000. Davis R M Inc. acquired a new position in iShares Russell 1000 ETF during the 2nd quarter worth $260,000. Finally, Blue Chip Wealth Management Inc. acquired a new position in iShares Russell 1000 ETF during the 1st quarter worth $265,000.
Top 5 Blue Chip Stocks To Own Right Now: Cabot Microelectronics Corporation(CCMP)
Advisors' Opinion:- [By Logan Wallace]
Cabot Microelectronics (NASDAQ: CCMP) and Analog Devices (NASDAQ:ADI) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Cabot Microelectronics (CCMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
News coverage about Cabot Microelectronics (NASDAQ:CCMP) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cabot Microelectronics earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave news stories about the semiconductor company an impact score of 46.640513544039 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Top 5 Blue Chip Stocks To Own Right Now: Rosetta Resources Inc.(ROSE)
Advisors' Opinion:- [By Ethan Ryder]
Get a free copy of the Zacks research report on Rosehill Resources (ROSE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
Shares of Rosehill Resources Inc (NASDAQ:ROSE) have earned an average recommendation of “Buy” from the eight analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $11.00.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Rosehill Resources Inc Class A (ROSE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 5 Blue Chip Stocks To Own Right Now: Lyon William Homes(WLH)
Advisors' Opinion:- [By Max Byerly]
William Lyon Homes (NYSE:WLH) had its price objective cut by Citigroup from $29.00 to $27.00 in a research report report published on Wednesday morning. They currently have a neutral rating on the construction company’s stock.
- [By Ethan Ryder]
News articles about William Lyon Homes (NYSE:WLH) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. William Lyon Homes earned a news impact score of 0.19 on Accern’s scale. Accern also gave media coverage about the construction company an impact score of 48.3603279087369 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
- [By Motley Fool Transcribers]
William Lyon Homes (NYSE:WLH)Q4 2018 Earnings Conference CallFeb. 14, 2019, 12:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Top 5 Blue Chip Stocks To Own Right Now: Ryerson Holding Corporation(RYI)
Advisors' Opinion:- [By Ethan Ryder]
Shares of Ryerson Holding (NYSE:RYI) have been given a consensus rating of “Hold” by the eight analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $11.69.
- [By Lee Jackson]
This top small-cap play could make sense for more aggressive accounts. Ryerson Holdings Inc. (NYSE: RYI) offers a line of stainless steel, aluminum, carbon steel and alloy steels, as well as nickel and red metals in various shapes and forms, including coils, sheets, rounds, hexagons, square and flat bars, plates, structurals and tubings.
- [By Lee Jackson]
Ryerson
This is a top small-cap play that could make sense for more aggressive accounts. Ryerson Holdings Inc. (NYSE: RYI) offers a line of stainless steel, aluminum, carbon steel and alloy steels, as well as nickel and red metals in various shapes and forms, including coils, sheets, square and flat bars, plates and tubing.
Top 5 Blue Chip Stocks To Own Right Now: ESSA Pharma Inc.(EPIX)
Advisors' Opinion:- [By Lisa Levin]
Losers Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering. InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday. Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81. Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections. Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results. LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss. Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit. Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings. Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss. Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight. Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings. The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results. Arcadia Biosciences, Inc. (N - [By Ethan Ryder]
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment